🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Vaborem 1 g/1 g powder for concentrate for solution for infusion

    A.Menarini Australia Pty Limited

    Suspected or confirmed Gram negative infections

    phase 2 small molecule active

    1 trial

  2. Valemetostat Tosylate, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Valemetostat Tosylate

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Vectibix 20 mg/ml concentrate for solution for infusion, VALPROIC ACID, VALPROIC ACID, Irinotecan Accord 20 mg/ml concentrato per soluzione perinfusione

    Fondazione Telethon ETS

    RAS/BRAF wild-type metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  4. Veklury 100 mg powder for concentrate for solution for infusion

    MEDA Pharma GmbH & Co. KG

    COVID-10 infection

    phase 2 small molecule active

    1 trial

  5. Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  6. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  8. Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione

    Istituto Gentili S.r.l.

    metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  9. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  10. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    melanoma brain metastases

    phase 2 small molecule active

    1 trial

  11. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  12. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  13. YTB323, Flebogamma DIF 50 mg/ml solution for infusion, TOCILIZUMAB, FLUDARABINE PHOSPHATE, CYCLOPHOSPHAMIDE

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  14. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  15. ZENGAC “500 mg Polvere per soluzione per infusione e per uso orale”, Plenvu, polvere per soluzione orale, SELG ESSE polvere per soluzione orale, Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Vancomicina Mylan 500 mg polvere per soluzione per infusione

    Istituto Gentili S.r.l.

    unresectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  16. Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile

    Astellas Pharma GmbH

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  17. Zejula 100 mg hard capsules, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  18. Zelvina 10 mg hard capsules, Zelvina 25 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 5 mg hard capsules

    Incyte

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  19. Zercepac 150 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  20. Zimberelimab, Trodelvy 200 mg powder for concentrate for solution for infusion

    Fondazione Telethon ETS

    Muscle-Invasive Bladder cancer

    phase 2 small molecule active

    1 trial

  21. Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Solid tumor

    phase 2 small molecule active

    1 trial

  22. [177Lu]-NeoB solution for infusion, AAA503

    Advanced Accelerator Applications

    Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.

    phase 2 small molecule active

    1 trial

  23. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  24. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources